From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

Analysts have set 12-month price targets for AbbVie, revealing an average target of $230.75, a high estimate of $255.00, and a low estimate of $205.00. Marking an increase of 2.21%, the current ...

While the stock market has been on a strong winning streak recently, you should only be putting cash into stocks that you ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...